A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma Clinical Trial

Official title:

A Phase 1/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 Monotherapy, or in Combination With Pomalidomide, With and Without Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ParadigMM-1B)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03287908
• Other study ID #: 20170122
• Secondary ID: 2017-001997-41
• Status: Terminated
• Phase: Phase 1
• Start date: November 13, 2017
• Est. completion date: June 30, 2023

Study information

• Verified date: October 2023
• Source: Amgen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of the phase 1 part of the study is to evaluate safety and tolerability of AMG 701 monotherapy to identify the RP2D for AMG 701 monotherapy followed by a dose-confirmation part to gather further safety data for AMG 701 monotherapy at the RP2D in adult subjects with relapsed/refractory multiple myeloma (RRMM). In addition, this study will include a sequential dose exploration part to identify the RP2D of AMG 701 in combination with pomalidomide, with and without dexamethasone (AMG 701-P+/-d). Phase 2 will consist of the dose-expansion part to gain further efficacy and safety experience with AMG 701 monotherapy in adult subjects with RRMM.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 174
• Est. completion date: June 30, 2023
• Est. primary completion date: June 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Multiple myeloma meeting the following criteria:
• Pathologically-documented diagnosis of multiple myeloma that is relapsed or is

refractory as defined by the following:

• Relapsed after > or = 3 lines of prior therapy that must include all approved and available therapies deemed eligible by the investigator, inclusing at a minimum of a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and, where approved and available, a CD38-directed cytolytic antibody in combination in the same line or separate lines of treatment OR refractory to PI, IMiD, and CD38- directed cytolytic antibody,
• Subjects who could not tolerate a PI, IMiDs, or a CD38-directed cytolytic antibody are eligible to enroll in the study.
• Measurable disease as per IMWG response criteria
• Eastern Cooperative Oncology Group (ECOG) Performance Status of = 2

Inclusion criteria specific to AMG 701-P±d include:

• Subjects must have received = 2 lines of prior therapy that must include a proteasome inhibitor (PI), lenalidomide, and where approved and available a CD38-directed antibody. These therapies may be in the same line or separate lines of treatment.
• Subjects must have responded to at least 1 prior line with at least a PR.
• Subjects that have previously received pomalidomide must not have been removed from therapy due to toxicity attributable to pomalidomide and must be at least 6 months from their last dose of pomalidomide.
• Subjects must not have known intolerance to doses of dexamethasone up to 40 mg weekly (20 mg weekly if > 75 years).

Exclusion Criteria:

• Known extramedullary relapse in the absence of any measurable medullary involvement
• Known central nervous system involvement by multiple myeloma
• Autologous stem cell transplantation less than 90 days prior to study day 1
• Recent history of primary plasma cell leukemia (within last 6 months prior to enrollment) or evidence of primary or secondary plasma cell leukemia at the time of screening
• Waldenstrom's macroglobulinemia
• Prior amyloidosis (subjects with multiple myeloma with asymptomatic deposition of amyloid plaques found on biopsy would be eligible if all other criteria are met)
• Treatment with systemic immune modulators including, but not limited to, nontopical systemic corticosteroids (unless the dose is = 10 mg/day prednisone or equivalent), cyclosporine, and tacrolimus within 2 weeks before study day 1
• Last anticancer treatment (chemotherapy, IMiD, PI, molecular targeted therapy) < 2 weeks prior to study day 1 or treatment with a therapeutic antibody less than 4 weeks prior to study day 1 as well as systemic radiation therapy within 28 days prior to study day 1 or focal radiotherapy within 14 days prior to study day 1.
• Prior treatment with any drug or construct that targets BCMA on tumor cells (eg, other bispecific antibody constructs, antibody drug conjugates, or CAR-T cells), other than Group C where prior treatment with GSK2857916 (belantamab mafodotin) is required.

Exclusion criteria specific to AMG 701-P±d include:

• History of serious hypersensitivity associated with thalidomide, pomalidomide, or lenalidomide (> grade 3).
• Multiple myeloma with IgM subtype.
• POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
• Contraindication to pomalidomide or dexamethasone.
• Glucocorticoid therapy within 14 days prior to randomization that exceeds a cumulative dose of 160 mg of dexamethasone or equivalent dose of other corticosteroids.
• Treatment with systemic immune modulators including, but not limited to, non-topical systemic corticosteroids (unless the dose is = 10 mg/day prednisone or equivalent), cyclosporine, and tacrolimus within 2 weeks before study day 1 or 4 weeks before study day 1 for Phase 1 dose-confirmation.
• Female subjects of childbearing potential with a positive pregnancy test assessed within 14 days prior to first dose of study drugs and/or a positive urine pregnancy test within 24 hours prior to first dose. In addition, females of childbearing potential unwilling to undergo pregnancy testing weekly during the first 4 weeks of pomalidomide use followed by pregnancy testing every 4 weeks in females with regular menses or every 2 weeks in females with irregular menstrual cycles.
• Male subjects with a female partner of childbearing potential and female subjects of childbearing potential who are unwilling to use 2 methods of contraception (1 of which must be highly effective during the study and for an additional 75 days (females) and 135 days (males) after receiving the last dose of AMG 701, or 28 days after the last dose pomalidomide (males and females) or dexamethasone (females), whichever occurs later.
• Females who are lactating/breastfeeding or who plan to breastfeed while on study through 75 days after receiving the last dose of AMG 701, or 28 days after the last dose pomalidomide or dexamethasone, whichever occurs later.
• Females planning to become pregnant while on study through 75 days after receiving the last dose of AMG 701 or 28 days after the last dose pomalidomide or dexamethasone, whichever occurs later.
• Male subjects with a pregnant partner who are unwilling to practice abstinence or use a latex or synthetic condom (even if they have had a vasectomy with medical confirmation of surgical success) during treatment (including during dose interruptions) and for an additional 135 days after the last dose of AMG 701, or 28 days after the last dose pomalidomide, whichever occurs later.
• Males who are unwilling to abstain from sperm donation while on study through 135 days after receiving the last dose of AMG 701 or 28 days after the last dose pomalidomide, whichever occurs later.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Relapsed/Refractory Multiple Myeloma

Intervention

Drug:
• AMG 701
Subjects will receive IV infusions of AMG 701.
• Pomalidomide
Subjects will receive oral capsules of pomalidomide.
• Dexamethasone
Subjects will receive IV injections or oral dexamethasone.

Locations

Country	Name	City	State
Australia	Peter MacCallum Cancer Centre	Melbourne	Victoria
Australia	The Alfred Hospital	Melbourne	Victoria
Australia	Princess Alexandra Hospital	Woolloongabba	Queensland
Canada	McGill University Health Centre Glen Site	Montreal	Quebec
Canada	University Health Network-Princess Margaret Cancer Centre	Toronto	Ontario
Germany	Universitätsklinikum Heidelberg	Heidelberg
Germany	Universitätsklinikum Schleswig Holstein Campus Kiel	Kiel
Germany	Universitaetsklinikum Wuerzburg	Wuerzburg
Japan	Kanazawa University Hospital	Kanazawa-shi	Ishikawa
Japan	Kobe City Medical Center General Hospital	Kobe-shi	Hyogo
Japan	The Cancer Institute Hospital of Japanese Foundation for Cancer Research	Koto-ku	Tokyo
Japan	Gunma University Hospital	Maebashi-shi	Gunma
Japan	Nagoya City University Hospital	Nagoya-shi	Aichi
Japan	National Hospital Organization Okayama Medical Center	Okayama-shi	Okayama
Netherlands	Universitair Medisch Centrum Groningen	Groningen
Netherlands	Maastricht Universitair Medisch Centrum	Maastricht
Netherlands	Universitair Medisch Centrum Utrecht	Utrecht
United States	Winship Cancer Institute Emory U	Atlanta	Georgia
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	Levine Cancer Institute	Charlotte	North Carolina
United States	University of Chicago Medical Center - Multiple Myeloma Research Consortium	Chicago	Illinois
United States	Hackensack University Medical Center	Hackensack	New Jersey
United States	Icahn School of Medicine at Mount Sinai	Hackensack	New Jersey
United States	University of Texas MD Anderson Cancer Center	Houston	Texas
United States	Mayo Clinic Florida	Jacksonville	Florida
United States	University of Arkansas for Medical Sciences Myeloma Institute Slot 816	Little Rock	Arkansas
United States	The Medical College of Wisconsin	Milwaukee	Wisconsin
United States	Columbia University Medical Center	New York	New York
United States	New York Presbyterian Hospital, Weill Cornell Medical College	New York	New York
United States	Mayo Clinic	Rochester	Minnesota
United States	Washington University	Saint Louis	Missouri
United States	University of Utah Huntsman Cancer Institute	Salt Lake City	Utah
United States	Mayo Clinic - Arizona	Scottsdale	Arizona
United States	Wake Forest Baptist Health	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Amgen

Countries where clinical trial is conducted

United States,  Australia,  Canada,  Germany,  Japan,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of subjects with dose-limiting toxicities (DLTs)		28 days
Primary	Number of subjects with treatment emergent adverse events (TEAEs)		60 months
Primary	Number of subjects with treatment-related adverse events		60 months
Primary	Number of subjects with disease-related adverse events		60 months
Primary	Number of subjects with clinically-significant changes in vital signs		48 months
Primary	Number of subjects with clinically-significant changes in physical examination measurements		48 months
Primary	Number of subjects with clinically-significant changes in electrocardiogram (ECG) measurements		48 months
Primary	Number of subjects with clinically-significant changes in clinical laboratory tests		48 months
Secondary	Pharmacokinetic parameter of AMG 701: Maximum concentration (Cmax)		12 weeks
Secondary	Pharmacokinetic parameter of AMG 701: Time of maximum concentration (Tmax)		12 weeks
Secondary	Pharmacokinetic parameter of AMG 701: Area under the concentration-time curve (AUC)		12 weeks
Secondary	Pharmacokinetic parameter of AMG 701: Steady state concentration (Css)		12 weeks
Secondary	Anti-tumor activity: Overall response rate	Efficacy parameter measured by International Myeloma Working Group (IMWG) response criteria. Best overall response of stringent CR (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR).	48 months
Secondary	Anti-tumor activity: Best overall response of stringent complete response (sCR)	Efficacy parameter measured by International Myeloma Working Group (IMWG) response criteria.	48 months
Secondary	Anti-tumor activity: Best overall response of complete response (CR)	Efficacy parameter measured by International Myeloma Working Group (IMWG) response criteria.	48 months
Secondary	Anti-tumor activity: Best overall response of very good partial response (VGPR)	Efficacy parameter measured by International Myeloma Working Group (IMWG) response criteria.	48 months
Secondary	Anti-tumor activity: Best overall response of partial response (PR)	Efficacy parameter measured by International Myeloma Working Group (IMWG) response criteria.	48 months
Secondary	Anti-tumor activity: Duration of response	Efficacy parameter measured by International Myeloma Working Group (IMWG) response criteria. Defined as time from the first PR or better to disease progression or death.	48 months
Secondary	Anti-tumor activity: Time to response	Efficacy parameter measured by International Myeloma Working Group (IMWG) response criteria.	48 months
Secondary	Anti-tumor activity: Progression-free survival	Efficacy parameter measured by International Myeloma Working Group (IMWG) response criteria. Defined as time from start of treatment until disease progression or death.	48 months
Secondary	Anti-tumor activity: Overall survival	Defined as time from start of treatment until death due to any cause.	60 months
Secondary	Anti-tumor activity: Number of subjects with minimum residual disease negative complete response	Efficacy parameter measured by International Myeloma Working Group (IMWG) response criteria.	48 months
Secondary	Pharmacokinetic parameter of AMG 701: Trough concentration (Ctrough)		12 weeks

External Links

•   AmgenTrials clinical trials website